Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.
GS-1811 is designed to selectively deplete immune system-suppressing T regulatory cells that infiltrate the area in and around tumors, giving the body's immune system a better chance at fighting off the cancer. "GS-1811, with its potential new pathway of activating the immune system, gives us the opportunity to potentially change the standard of care with a treatment works from inside cancerous cells to shrink solid tumors," said Dr.Richard Murray
Source: News Formal (newsformal.com)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drugJounce Therapeutics Inc. shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc. would completely...
Source: MarketWatch - 🏆 3. / 97 Read more »
Gilead buys out rights to cancer therapy from Jounce for $67 mlnGilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday. Seems a little low, no? Big pharma's estimate sales in vaccines for 2023 is predicted to be 6B... Follow the money
Source: Reuters - 🏆 2. / 97 Read more »
Gilead buys remaining rights to cancer immunotherapy drug from partner Jounce - San Francisco Business Times$GILD buys out rights to early-stage $JNCE cancer drug as part of ongoing efforts to beef up its cancer drug pipeline.
Source: SFBusinessTimes - 🏆 78. / 68 Read more »
Samsung contributes $1,101,000 to Second Harvest of Silicon ValleyApril Lee, Corporate Social Responsibility Manager, Samsung Leslie Bacho, CEO, Second Harvest of Silicon Valley
Source: KPIXtv - 🏆 443. / 53 Read more »
Year in Review: Five notable tech bills passed this year as Silicon Valley faces populist backlashCongress was able to pass a few small yet significant pieces of technology-related legislation amid growing populist hostility toward Big Tech from the Left over profit margins and the Right over culture war issues.
Source: dcexaminer - 🏆 6. / 94 Read more »
S.F. grocery delivery giant Instacart trims valuation - Silicon Valley Business JournalInstacart cut its meaty valuation back in March. Here's how much it's just trimmed it again. bayarea technews
Source: svbizjournal - 🏆 334. / 59 Read more »